CRISPR/Cas9-based Pten knock-out and Sleeping Beauty Transposon-mediated Nras knock-in induces hepatocellular carcinoma and hepatic lipid accumulation in mice

Cancer Biology & Therapy
Mingming Gao, Dexi Liu

Abstract

Both Pten and Nras are downstream mediators of receptor tyrosine kinase activation that plays important roles in controlling cell survival and proliferation. Here, we investigated whether and how Pten loss cross-talks with Nras activation in driving liver cancer development in mice. Somatic disruption of hepatic Pten and overexpression of Nras were achieved in out-bred immunocompetent CD-1 mice through a hydrodynamic delivery of plasmids carrying Sleeping Beauty transposon-based integration of Nras and the CRISPR/Cas9-mediated Pten knockout system. Concurrent Pten knockout and Nras knock-in induced hepatocellular carcinoma, while individual gene manipulation failed. Tumor development was associated with liver fibrosis, hyperlipidemia, hepatic deposition of lipid droplets and glycogen, and hepatomegaly. At the molecular level, lipid droplet formation was primarily contributed by upregulated expression of genes responsible for lipogenesis and fatty acid sequestration, such as Srebpf1, Acc, Pparg and its downstream targets. Our findings demonstrated that Pten disruption was synergized by Nras overexpression in driving hepatocyte malignant transformation, which correlated with extensive formation of lipid droplets.

References

Jul 1, 1996·Pathology International·S H YangM Kojiro
Feb 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·K PodsypaninaR Parsons
Feb 11, 2004·Proceedings of the National Academy of Sciences of the United States of America·Bangyan StilesHong Wu
Jun 17, 2004·The Journal of Clinical Investigation·Yasuo HorieToru Nakano
Nov 16, 2005·Proceedings of the National Academy of Sciences of the United States of America·Corey M CarlsonDavid A Largaespada
Apr 13, 2007·Biochimica Et Biophysica Acta·Krishnaraj RajalingamStefan Albert
Sep 6, 2007·Proceedings of the National Academy of Sciences of the United States of America·Aaron D TwardJ Michael Bishop
Jan 17, 2009·Cancer Research·Stephen M WiesnerJohn R Ohlfest
Jan 30, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·UNKNOWN International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia
May 30, 2009·Nature Methods·Zoltán IvicsZsuzsanna Izsvák
Jan 19, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Beate K StraubPeter Schirmacher
Mar 9, 2010·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Patricia T Bozza, João P B Viola
Mar 12, 2010·Critical Reviews in Biochemistry and Molecular Biology·Maggie S Strable, James M Ntambi
Sep 10, 2010·Journal of Biosciences·Nirmala Yabaluri, Murali D Bashyam
Sep 28, 2010·World Journal of Gastroenterology : WJG·Marion PeyrouMichelangelo Foti
Mar 25, 2011·Nature Reviews. Cancer·M Christine HollanderPhillip A Dennis
Dec 17, 2011·Journal of Hepatology·Lars P BechmannAli Canbay
Feb 14, 2012·Journal of Hepatology·György BaffyStephen H Caldwell
Feb 1, 2014·The American Journal of Pathology·Xin Chen, Diego F Calvisi
Sep 14, 2014·Nature Medicine·Ramona RudalskaLars Zender
May 10, 2016·Nature Reviews. Disease Primers·Josep M LlovetGregory Gores
May 14, 2016·Genetics and Molecular Research : GMR·M F LiD D Zhang
Sep 3, 2016·International Journal of Molecular Sciences·Shiro Koizume, Yohei Miyagi
Jan 25, 2017·PPAR Research·Tommaso MelloAndrea Galli

❮ Previous
Next ❯

Citations

Jan 25, 2018·American Journal of Physiology. Renal Physiology·Huizhen WangWenjian Wang
Sep 23, 2020·Journal of Cellular Physiology·Baohong Zhang
Sep 27, 2020·Genes·Ilayda AtesRenee N Cottle
Jun 10, 2018·Clinics and Research in Hepatology and Gastroenterology·Robin LoeschSabine Colnot

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
PCR

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

Related Papers

Harefuah
M Goldberg, Y Gruenbaum
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Susie A LeeXin Chen
Proceedings of the National Academy of Sciences of the United States of America
Corey M CarlsonDavid A Largaespada
The Journal of Biological Chemistry
I LYON, R P GEYER
© 2022 Meta ULC. All rights reserved